| Trial ID: | L5265 |
| Source ID: | NCT01542242
|
| Associated Drug: |
Liraglutide
|
| Title: |
Liraglutide Use in Prader-Willi Syndrome
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2|Prader Willi Syndrome
|
| Interventions: |
DRUG: Liraglutide
|
| Outcome Measures: |
Primary: Hemoglobin A1C, Change from baseline in A1C at 12 months | Secondary: Fasting Blood Glucose (mmol/L), Change from baseline in fasting blood glucose at 12 months|Fasting Blood Insulin level, Change from baseline in fasting blood insulin at 12 months|Body Weight (kg), Change from baseline in body weight at 12 months|Fasting Lipid Profile, Change from baseline in fasting lipid profile at 12 months|Hip Circumference (cm), Change from baseline in hip circumference at 12 months|Total Body Adipose Tissue Distribution (whole body Computed Tomography), Change from baseline in total body adipose tissue distribution at 12 months
|
| Sponsor/Collaborators: |
Sponsor: Vancouver General Hospital | Collaborators: Novo Nordisk A/S
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
1
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-02
|
| Completion Date: |
2013-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-12-09
|
| Locations: |
Vancouver General Hospital - Diamond Center, Vancouver, British Columbia, V5Z 1M9, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT01542242
|
